Trial
NCT06370663
First-line Treatment for Unresectable Locally Advanced Distal Cholangiocarcinoma Combining Radiotherapy and HAIC
Phase IITERMINATEDSAFETYConfidence: HIGH
Sponsor
Shandong Cancer Hospital and Institute
Collaborators
—
Condition
Intrahepatic Cholangiocarcinoma
Intervention
Radiotherapy
Why stopped
Study was terminated due to unacceptable treatment-related toxicity that raised safety concerns and outweighed the potential benefits.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-06-25